Publications by authors named "Pradeep Anjaneya"
Article Synopsis
- Biosimilars are approved treatment options based on comparisons to reference biologics, but concerns about their long-term safety remain, prompting a review of data from eight Sandoz biosimilars over up to 18 years.
- Cumulative exposure data showed over 1.3 billion patient treatment days for seven biosimilars and 1.8 million doses for one, indicating significant real-world use.
- The analysis concluded that the overall benefit-risk profiles of these Sandoz biosimilars are favorable and consistent with their reference biologics.
